Research Topics
Genomes and GenesSpecies | Chloe ThioSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Hepatitis B virus treatment in HIV-infected patientsChloe L Thio
The Johns Hopkins University, Baltimore, MD, USA
Top HIV Med 14:170-5. 2006..Thio, MD, at the 9th Annual Ryan White CARE Act Update in Washington, DC. The original presentation is available as a Webcast at www.iasusa.org...
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohortChloe L Thio
Johns Hopkins University, Baltimore, Maryland 21205, USA
AIDS 27:191-201. 2013..To understand the HIV-hepatitis B virus (HBV) epidemic from a global perspective by clinically and virologically characterizing these viruses at the time of antiretroviral therapy (ART) initiation in a multinational cohort...- Treatment of HIV/HBV coinfection: clinical and virologic issuesChloe L Thio
Department of Medicine, Johns Hopkins University, 424 North Bond St, Baltimore, MD 21231, USA
AIDS Rev 9:40-53. 2007..Effective antiviral treatment can precipitate immune reconstitution disease resulting in serious hepatic flare and precipitating liver decompensation. Clearly, more data are needed to more effectively treat HIV/HBV coinfection... - Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patientsChloe L Thio
Johns Hopkins University, Baltimore, MD, USA
Antivir Ther 12:H25-31. 2007..In addition, noninvasive methods for classifying liver disease stage are discussed, as are special considerations that are needed for individuals coinfected with HIV... 
Host genetic factors and antiviral immune responses to hepatitis C virusChloe L Thio
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA
Clin Liver Dis 12:713-26, xi. 2008..Results of some of these studies complement knowledge gained from immunology studies, and others offer new insights into HCV biology. This review summarizes published studies on variation in immune-response genes and HCV outcomes...- Hepatitis B and human immunodeficiency virus coinfectionChloe L Thio
Johns Hopkins University, Division of Infectious Diseases, Baltimore, MD 21205, USA
Hepatology 49:S138-45. 2009..Further research is also needed to determine the mechanism(s) for the increased liver disease progression and optimal treatment goals... - Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black boxChloe L Thio
Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
Clin Infect Dis 41:1035-40. 2005 - Mannose binding lectin genotypes influence recovery from hepatitis B virus infectionChloe L Thio
Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
J Virol 79:9192-6. 2005..76; 95% CI, 1.02 to 3.01; P = 0.04). These data are consistent with the hypothesis that functional MBL plays a central role in the pathogenesis of acute hepatitis B... - Racial differences in HLA class II associations with hepatitis C virus outcomesC L Thio
Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231 1001, USA
J Infect Dis 184:16-21. 2001..36; 95% CI, 1.23-4.52) and its DQB1*0201 haplotype. These results support a role for class II alleles in the immune response to HCV and underscore the importance of studying genetic associations in an ethnically diverse cohort... - Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapyChloe L Thio
Johns Hopkins University, Baltimore, MD, USA
Antivir Ther 15:487-91. 2010..This review will discuss studies of drug-resistant HBV in HIV-infected persons including drug-resistant mutations that have been identified and clinical sequelae of these mutations... - Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infectionChloe L Thio
Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Virol 77:12083-7. 2003..The associations with class I alleles are consistent with a previously implicated role for CD8-mediated cytolytic-T-cell response in determining the outcome of an acute HBV infection... - An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infectionC L Thio
Department of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
Genes Immun 5:294-300. 2004..Further study of this polymorphism and haplotype is needed to understand these associations and the role of TNF-alpha in determining outcomes of HCV infection... - HLA-Cw*04 and hepatitis C virus persistenceChloe L Thio
Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, USA
J Virol 76:4792-7. 2002..Further investigation is needed to understand the relationship between class I alleles and HCV clearance... - Changes in hepatitis B virus DNA levels with acute HIV infectionChloe L Thio
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Infect Dis 38:1024-9. 2004..Acute HIV infection is not consistently associated with an increased blood HBV DNA level. Additional research is needed to understand the mechanism for the unexpected reductions in HBV DNA levels associated with acute HIV infection... - Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infectionChloe L Thio
Department of Medicine, Johns Hopkins Medical Institutions, 1503 E Jefferson Street, Baltimore, MD 21231, USA
J Virol 78:11258-62. 2004..32, P = 0.04). These data suggest that CTLA4 influences recovery from HBV infection, which is consistent with the emerging role of T regulatory cells in the pathogenesis of disease... - HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)Chloe L Thio
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Lancet 360:1921-6. 2002..Our aim was to examine liver-related mortality among people at risk for HIV-1 and HBV infections... - Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatmentChloe L Thio
Assistant Professor of Medicine, Johns Hopkins University, Baltimore, Maryland 21231 1001, USA
Semin Liver Dis 23:125-36. 2003..As new drugs currently in clinical trials become available, therapy for chronic hepatitis B will enter the promising era of combination therapy... - The HBV drug entecavir - effects on HIV-1 replication and resistanceMoira A McMahon
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
N Engl J Med 356:2614-21. 2007..Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens... - IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infectionMaureen P Martin
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC Frederick, NCI Frederick, Frederick, Maryland, USA
J Infect Dis 202:1749-53. 2010..99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV... - Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearancePing An
Laboratory of Genomic Diversity, Science Applications International Corportation Frederick, MD, USA
J Infect Dis 198:1159-65. 2008..77-11.6]) was also strongly associated with viral clearance. No association was found among those with hemophilia. These results suggest that IL18 promoter polymorphism may affect the outcome of HCV infection in certain groups... - Management of chronic hepatitis B in the HIV-infected patientChloe L Thio
Johns Hopkins University, Baltimore, Maryland, USA
AIDS Read 14:122-9, 133, 136-7. 2004..It is anticipated that we are entering a period of combination therapy for chronic hepatitis B, but the ideal combination needs to be elucidated... - Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatusNed Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Neurovirol 16:335-41. 2010..Mild neurocognitive changes over time among older HIV+ individuals are likely to reflect age associated pathophysiological mechanisms including cerebrovascular risk factors... - Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcomeAnn L Truelove
Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD, USA
Int J Immunogenet 35:255-64. 2008..01-0.04). These results suggest that IL10 and IL20 gene variants influence HBV infection outcome and encourage the pursuit of further studies of these cytokines in HBV pathogenesis... - Incidence and epidemiology of anal cancer in the multicenter AIDS cohort studyGypsyamber D'Souza
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 48:491-9. 2008..To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study)... - Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis BChristopher J Hoffmann
Aurum Institute for Health Research, Johannesburg, South Africa
AIDS 21:1301-8. 2007..Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa... - IL28B and the control of hepatitis C virus infectionAshwin Balagopal
Division of Infectious Diseases, Center for Viral Hepatitis, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Gastroenterology 139:1865-76. 2010..We review the genetic studies that uncovered the association between IL28B and HCV clearance, the biology of IFN-λ3, the clinical implications of the genetic association, and areas of future research... - Liver disease in the HIV-infected individualJennifer C Price
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
Clin Gastroenterol Hepatol 8:1002-12. 2010.... - Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelinesStephen A Berry
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2100, USA
Sex Transm Infect 86:481-4. 2010..This study determined GC/CT testing rates in a clinical HIV cohort before and after 2003 when the US Centers for Disease Control and Prevention issued guidelines for GC/CT screening... - Tenofovir for the treatment of hepatitis B virusAlice M Jenh
Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
Pharmacotherapy 29:1212-27. 2009..In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir... - Hepatitis B and long-term HIV outcomes in coinfected HAART recipientsChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
AIDS 23:1881-9. 2009..Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized... - Genetic variation in IL28B and spontaneous clearance of hepatitis C virusDavid L Thomas
Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland 21205, USA
Nature 461:798-801. 2009..To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection... - Clinical implications of HIV and hepatitis B co-infection in Asia and AfricaChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Lancet Infect Dis 7:402-9. 2007..This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted... - Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistenceChloe L Thio
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
J Virol 81:441-5. 2007.... - Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical eventsChristopher J Hoffmann
Aurum Institute for Health Research, Johannesburg, South Africa
AIDS 22:67-74. 2008..To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting... - Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis BChloe L Thio
Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
J Immunol 181:7944-7. 2008.... - Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virusTimothy L Mosbruger
Johns Hopkins University, Baltimore, MD, USA
J Infect Dis 201:1371-80. 2010..In this large-scale analysis of 1426 genotyped SNPs in 112 candidate genes, we identified 4 gene regions that are likely candidates for a role in HCV clearance or persistence in both African Americans and European Americans... - High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, UgandaLara Stabinski
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Antivir Ther 16:405-11. 2011..Liver disease is a leading cause of mortality among HIV-infected persons in the United States and Europe. However, data regarding the effects of HIV and antiretroviral therapy (ART) on liver disease in Africa are sparse... - Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individualsPeter A Revill
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
AIDS 21:1701-10. 2007..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy... - Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
AIDS 20:863-70. 2006..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy... - HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infectionSalim I Khakoo
Liver Group, Division of Infection, Inflammation, and Repair, Southampton University, Southampton 5016 6YD, UK
Science 305:872-4. 2004..The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV... - A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionYing Huang
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:985-90. 2007.... - Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptaseRobert A Domaoal
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520 8066, USA
J Biol Chem 283:5452-9. 2008..This study has important therapeutic implications as it establishes ETV as an inhibitor for HIV-1 RT and illustrates the mechanism of resistance by the M184V mutant... - Treatment of chronic hepatitis B in the HIV-infected patientChloe L Thio
Hopkins HIV Rep 15:9, 12. 2003 - Association of CTLA4 polymorphism with regulatory T cell frequencySowsan F Atabani
Division of Molecular Immunology, Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
Eur J Immunol 35:2157-62. 2005..These data implicate CTLA4 in regulatory T cell development, and provide a mechanism to account for the link between polymorphisms at this locus and the biological outcome of adaptive immune responses to self and to pathogens... - The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsJoe Sasadeusz
The Alfred Hospital, Melbourne, Victoria, Australia
AIDS 22:947-55. 2008.... - Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo
Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Clin Gastroenterol Hepatol 4:233-48. 2006..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature... - Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?Chloe L Thio
J Hepatol 44:1-3. 2006
Research Grants
- Hepatitis B treatment and HIV Infection in resources limited settingsChloe Thio; Fiscal Year: 2007..This proposal has a high likelihood for success given the investigative team's experience, the randomized clinical trial design, and the nesting in an existing study. ..
- Liver Disease and HIV-HBV Coinfection in the HAART eraChloe Thio; Fiscal Year: 2007..Given the experience of the investigative team and the well-characterized cohorts involved, the results from this proposal will yield insights into the management of HIV-HBV co-infected patients. ..
- Hepatitis B treatment and HIV Infection in resources limited settingsChloe L Thio; Fiscal Year: 2010..This proposal has a high likelihood for success given the investigative team's experience, the randomized clinical trial design, and the nesting in an existing study. ..